Rhode Island Medicaid restricts GLP-1 coverage to type 2 diabetes

Rhode Island's enacted fiscal year 2027 state budget ends Medicaid coverage of GLP-1 medications for weight management, effective October 1, 2026, according to research compiled by The RX Index ^[1]. Until that date, Rhode Island's Medicaid fee-for-service program still covers weight-management GLP-1s, including Zepbound (tirzepatide), on its preferred drug list, subject to prior authorization ^[1]. After October 1, the state's Medicaid program will cover GLP-1 drugs only for type 2 diabetes and other federally required conditions ^[1].

The change follows a pattern seen elsewhere. As of July 10, 2026, 11 state Medicaid programs covered GLP-1 drugs for obesity in adults, down from 13 in January 2026, according to the tracker, which cites KFF's January count as its baseline ^[1]. Utah's coverage pilot ended June 30, 2026, without renewal, and Massachusetts ended its weight-loss coverage on July 1, 2026 ^[1]. Once Rhode Island's restriction takes effect, the state will no longer count among those offering optional obesity coverage, based on the same tracking methodology ^[1].

Federal Medicaid law requires states to cover FDA-approved drugs for "medically accepted indications," but it specifically allows states to exclude drugs used for weight loss, which is why coverage differs so much from state to state ^[1]. That means semaglutide sold as Ozempic for diabetes must be covered in every state, but the same drug sold as Wegovy for obesity is covered in only a shrinking list of states ^[1]. Coverage for cardiovascular-risk reduction, obstructive sleep apnea, and noncirrhotic MASH (Wegovy injection only) is required nationwide because those are FDA-approved indications states cannot exclude ^[1].

Other states have shown these decisions can reverse. North Carolina dropped GLP-1 obesity coverage in October 2025 for budget reasons, then reinstated it in December 2025 ^[1]. Michigan took the opposite path, tightening its rules on January 1, 2026, to cover weight-loss GLP-1s only for enrollees with a body mass index of 40 or higher who have already tried other options and are trying to avoid bariatric surgery ^[1].

Why it matters for patients

For Rhode Island Medicaid enrollees taking Zepbound or another GLP-1 solely for weight management, coverage ends October 1, 2026, unless they have a qualifying diagnosis such as type 2 diabetes, established cardiovascular disease, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH ^[1]. Enrollees under 21 may still have a coverage pathway even after the adult benefit ends, because a federal Medicaid rule called EPSDT requires coverage of medically necessary treatment for anyone under 21, regardless of a state's adult exclusion policy ^[1]. The source material does not say whether Rhode Island Medicaid managed-care plans, which are run by private insurers under contract with the state, will follow the same restriction as the state's own fee-for-service program; that detail is not yet known from what's available here ^[1].

More broadly, Medicaid enrollees with obesity make up close to 40 percent of the adult Medicaid population, and Medicaid GLP-1 prescriptions grew roughly eightfold nationally, from about 1 million in 2019 to more than 8 million in 2024, which shows how much is at stake as states weigh the cost of continuing this coverage ^[1].

What happens next

Rhode Island's Medicaid GLP-1 coverage for weight management continues through September 30, 2026, and the restriction to diabetes-only coverage takes effect October 1, 2026, under the enacted FY2027 budget ^[1]. The tracker notes that state Medicaid coverage decisions have reversed before, as in North Carolina, so whether Rhode Island's restriction proves permanent is not yet known ^[1].